Bharat Biotech has submitted the data of the third phase trial of indigenous vaccine Covaxin. The expert group is expected to meet today, in which the results of the data can be considered. Bharat Biotech had released interim data for Phase III trials in March. It was said that it is up to 81% effective against the COVID-19 virus. The company has submitted this data to the Drug Controller General of India. The expert committee related to the clinical trial of the drug regulator will consider these results today. Earlier this month, the company said it would publish the results of Phase III trials in July and apply for a full license. As of now, Covaxin has been approved under emergency use only.